From the miRoncol archive: This historical update may contain promotional language or research findings that do not describe the current service. Retrospective research results do not establish prospective screening performance, and references to scientific prizes do not imply evaluation or endorsement of miRoncol or miCheckup. Do not rely on this archive for healthcare decisions; use the current product information and discuss screening decisions with a healthcare professional.
miRoncol Health is pleased to announce the appointment of Victoria Xu as its new Chief Executive Officer, effective April 2024.
As miRoncol’s first committed investor and advisor, and with a Master’s in Bioinformatics and Public Management, Victoria Xu will lead miRoncol Health’s mission to provide healthy individuals a new line of defense against cancer through real-time, blood-based multi-cancer risk assessment using microRNA (miRNA) technology. Passionate about prevention and sustainability, she champions responsible innovation that improves quality of life and planetary health.